What is the difference between Cartalax and Sigumir?

Cartalax: Tetrapeptide bioregulator from cartilage tissue; stimulates chondrocyte proliferation and extracellular matrix synthesis; normalizes gene expression in cartilage cells Sigumir: Tetrapeptide bioregulator targeting joint and bone tissue; modulates osteoblast and chondrocyte activity; reduces local joint inflammation; promotes extracellular matrix production

Is Cartalax FDA approved?

Cartalax is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

Is Sigumir FDA approved?

Sigumir is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is Cartalax administered in research settings?

In research settings, Cartalax is typically administered via the subcutaneous or oral routes. PeptideBase does not provide dosing or administration instructions.

How is Sigumir administered in research settings?

In research settings, Sigumir is typically administered via the subcutaneous or oral routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Cartalax vs Sigumir

Peptide Comparison

Cartalax vs Sigumir

Name: Cartalax vs Sigumir — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Skin & Cosmetic peptides.

Cartalax

Ala-Glu-Asp-Arg

Skin & JointNot EvaluatedResearch Only

Half-life: Unknown

6 providers listed

Full Cartalax profile →

Sigumir

Val-Glu-Pro-Arg

Skin & JointNot EvaluatedResearch Only

Half-life: Unknown

1 providers listed

Full Sigumir profile →

Bottom line

Cartalax is carried by more providers on PeptideBase (6 vs 1); otherwise the two are closely matched on the measures we track.

Quick Verdict

Cartalax

Evidence

Preclinical

Sigumir

Evidence

Review-level

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Sigumir
More provider options (6 vs 1)	Cartalax

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Cartalax

Sigumir

Mechanism Family

Skin & Cosmetic

Half-life

Unknown

FDA Status

not evaluated

Admin Routes

subcutaneous, oral

Availability

Research Only

Providers

6 listed

1 listed

Avail. Notes

Russian joint/cartilage peptide bioregulator (Khavinson Institute). Not FDA-approved. Not on any FDA list. Research chemical in US.

Russian joint peptide bioregulator (Khavinson Institute). Not FDA-approved. Not on any FDA list. Research chemical in US.

Research Evidence

Cartalax

PreclinicalIn vitro · 1 key study · most recent 2023

Sigumir

Review-levelReview · 2 key studies · most recent 2023

Research Citations

Cartalax

In vitro2023 · Advances in Gerontology

KE peptide regulates SIRT1, PARP1, PARP2 gene expression and protein synthesis in human mesenchymal stem cell…

Sigumir

Review2023 · Biomolecules

Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters

Review2021 · Molecules

Peptide Regulation of Gene Expression: A Systematic Review

About Cartalax

Tetrapeptide bioregulator from cartilage tissue; stimulates chondrocyte proliferation and extracellular matrix synthesis; normalizes gene expression in cartilage cells

Research Areas

cartilage regenerationjoint repairchondrocyte function support

About Sigumir

Tetrapeptide bioregulator targeting joint and bone tissue; modulates osteoblast and chondrocyte activity; reduces local joint inflammation; promotes extracellular matrix production

Research Areas

joint tissue repairbone and cartilage supportanti-inflammatory (joint)mobility improvement

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Cartalax

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Sigumir

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Price (per mg)

Cartalax

$2.75/mg

$2.06 – $3.00 range

12 vendors

View price index →Find providers →

Sigumir

Not enough vendor pricing yet.

Find Providers

Where to source these peptides

Providers offering

Cartalax

6 listed

Browse directory →

Providers offering

Sigumir

1 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Skin & Cosmetic Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated July 20, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). Cartalax vs Sigumir — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/cartalax/sigumir

https://peptidebase.io/peptides/compare/cartalax/sigumir Methodology License Download JSON Download CSV